1 |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
|
2 |
Ferlay J, Partensky C, Bray F. More deaths from pancreatic cancer than breast cancer in the EU by 2017[J]. Acta Oncol, 2016, 55(9/10): 1158-1160.
|
3 |
Lin QJ, Yang F, Jin C, et al. Current status and progress of pancreatic cancer in China[J]. World J Gastroenterol, 2015, 21(26): 7988-8003.
|
4 |
Mayo SC, Nathan H, Cameron JL, et al. Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent[J]. Cancer, 2012, 118(10): 2674-2681.
|
5 |
de Sá MC, Simão ANC, de Medeiros FA, et al. Cell adhesion molecules and plasminogen activator inhibitor type-1 (PAI-1) in patients with rheumatoid arthritis: influence of metabolic syndrome[J]. Clin Exp Med, 2018, 18(4): 495-504.
|
6 |
Bendas G, Borsig L. Heparanase in cancer metastasis: heparin as a potential inhibitor of cell adhesion molecules[J]. Adv Exp Med Biol, 2020, 1221: 309-329.
|
7 |
Bergmann F, Wandschneider F, Sipos B, et al. Elevated L1CAM expression in precursor lesions and primary and metastastic tissues of pancreatic ductal adenocarcinoma[J]. Oncol Rep, 2010, 24(4): 909-915.
|
8 |
Geismann C, Morscheck M, Koch D, et al. Up-regulation of L1CAM in pancreatic duct cells is transforming growth factor β1- and slug-dependent: role in malignant transformation of pancreatic cancer[J]. Cancer Res, 2009, 69(10): 4517-4526.
|
9 |
Mayer IA, Arteaga CL. The PI3K/AKT pathway as a target for cancer treatment[J]. Annu Rev Med, 2016, 67: 11-28.
|
10 |
Liang H, Mokrani A, Chisomo-Kasiya H, et al. Dietary leucine affects glucose metabolism and lipogenesis involved in TOR/PI3K/Akt signaling pathway for juvenile blunt snout bream Megalobrama amblycephala[J]. Fish Physiol Biochem, 2019, 45(2): 719-732.
|
11 |
Polivka J, Janku F. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway[J]. Pharmacol Ther, 2014, 142(2): 164-175.
|
12 |
Akinleye A, Avvaru P, Furqan M, et al. Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics[J]. J Hematol Oncol, 2013, 6(1): 88.
|
13 |
Sierra JR, Tsao MS. C-MET as a potential therapeutic target and biomarker in cancer[J]. Ther Adv Med Oncol, 2011, 3(1): S21-S35.
|
14 |
Ou SH, Kwak EL, Siwak-Tapp C, et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification[J]. J Thorac Oncol, 2011, 6(5): 942-946.
|
15 |
Li Y, Chen CQ, He YL, et al. Abnormal expression of E-cadherin in tumor cells is associated with poor prognosis of gastric carcinoma[J]. J Surg Oncol, 2012, 106(3): 304-310.
|
16 |
di Renzo MF, Olivero M, Giacomini A, et al. Overexpression and amplification of themet/HGF receptor gene during the progression of colorectal cancer[J]. Clin Cancer Res, 1995, 1(2): 147-154.
|
17 |
Garcia S, Dalès JP, Jacquemier J, et al. C-Met overexpression in inflammatory breast carcinomas: automated quantification on tissue microarrays[J]. Br J Cancer, 2007, 96(2): 329-335.
|
18 |
Radaeva S, Ferreira-Gonzalez A, Sirica AE. Overexpression of C-NEU and C-MET during rat liver cholangiocarcinogenesis: a link between biliary intestinal Metaplasia and mucin-producing cholangiocarcinoma[J]. Hepatology, 1999, 29(5): 1453-1462.
|
19 |
di Renzo MF, Poulsom R, Olivero M, et al. Expression of the Met/hepatocyte growth factor receptor in human pancreatic cancer[J]. Cancer Res, 1995, 55(5): 1129-1138.
|
20 |
Neuzillet C, Couvelard A, Tijeras-Raballand A, et al. High c-Met expression in stage Ⅰ‒Ⅱ pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis[J]. Histopathology, 2015, 67(5): 664-676.
|
21 |
Hervieu A, Kermorgant S. The role of PI3K in Met driven cancer: a recap[J]. Front Mol Biosci, 2018, 5: 86.
|
22 |
Marinkovich MP. Tumour microenvironment: laminin 332 in squamous-cell carcinoma[J]. Nat Rev Cancer, 2007, 7(5): 370-380.
|
23 |
Stemmler S, Parwez Q, Petrasch-Parwez E, et al. Association of variation in the LAMA3 gene, encoding the α-chain of laminin 5, with atopic dermatitis in a German case-control cohort[J]. BMC Dermatol, 2014, 14: 17.
|
24 |
Castro BGR, Dos Reis R, Cintra GF, et al. Predictive factors for surgical morbidities and adjuvant chemotherapy delay for advanced ovarian cancer patients treated by primary debulking surgery or interval debulking surgery[J]. Int J Gynecol Cancer, 2018, 28(8): 1520-1528.
|
25 |
Lincoln V, Cogan J, Hou Y, et al. Gentamicin induces LAMB3 nonsense mutation readthrough and restores functional laminin 332 in junctional epidermolysis bullosa[J]. PNAS, 2018, 115(28): E6536-E6545.
|
26 |
Svoboda M, Hlobilová M, Marešová M, et al. Comparison of suction blistering and tape stripping for analysis of epidermal genes, proteins and lipids[J]. Arch Dermatol Res, 2017, 309(9): 757-765.
|
27 |
Wang YH, Jin YX, Bhandari A, et al. Upregulated LAMB3 increases proliferation and metastasis in thyroid cancer[J]. Onco Targets Ther, 2018, 11: 37-46.
|
28 |
Pan ZF, Li L, Fang QL, et al. Analysis of dynamic molecular networks for pancreatic ductal adenocarcinoma progression[J]. Cancer Cell Int, 2018, 18: 214.
|
29 |
Jung SN, Lim HS, Liu LH, et al. LAMB3 mediates metastatic tumor behavior in papillary thyroid cancer by regulating c-MET/Akt signals[J]. Sci Rep, 2018, 8(1): 2718.
|
30 |
Huang WJ, Gu JY, Tao T, et al. MiR-24-3p inhibits the progression of pancreatic ductal adenocarcinoma through LAMB3 downregulation[J]. Front Oncol, 2019, 9: 1499.
|
31 |
Zhang H, Pan YZ, Cheung M, et al. LAMB3 mediates apoptotic, proliferative, invasive, and metastatic behaviors in pancreatic cancer by regulating the PI3K/Akt signaling pathway[J]. Cell Death Dis, 2019, 10(3): 230.
|